Programmed Death Ligand-1 Expression in Gliomas: A Study of Histopathological and Molecular Associations
Authors:
- 1 January 2021
- journal article
- research article
- Published by Medknow in Neurology India
- Vol. 69 (4) , 1005-1009
Abstract
Background: Gliomas are aggressive tumors with limited treatment options. Immunotherapy targets are under evaluation as new therapeutic targets in gliomas. Aims and Objectives: The aims of the study were to analyze expression of PDL1 in adult diffuse gliomas in World Health Organization grade II, III, and IV and to corelate its expression with demographic features, IDH-1, ATRX, and p-53 mutation status. Materials and Methods: This was a case series that included 30 cases of adult diffuse glioma. In all cases, a composite diagnosis including histologic type, grade, and molecular alterations was rendered. PDL1 testing was done by immunohistochemistry using PDL1 SP-263 antibody. Results: PDL1 expression was identified in 33.3% cases in tumor cells and in 6.67% cases in immune cells. All neoplasms with PDL1 expression were astrocytic tumors. PDL1 expression was significantly associated with IDH-1 immunonegative gliomas (P = 0.013). Conclusion: PDL1 is a novel therapeutic target in gliomas. The current study is an attempt to evaluate the expression of PDL1 over the varied spectrum of gliomas. Key Words:Keywords
This publication has 12 references indexed in Scilit:
- Programmed Death Ligand 1 Is a Negative Prognostic Marker in Recurrent Isocitrate Dehydrogenase-Wildtype GlioblastomaNeurosurgery, 2018
- Blocking the PD-1/PD-L1 pathway in glioma: a potential new treatment strategyJournal of Hematology & Oncology, 2017
- Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignanciesNeuro-Oncology, 2016
- The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summaryActa Neuropathologica, 2016
- ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an “integrated” diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastomaActa Neuropathologica, 2014
- B7-H3 and B7-H1 expression in cerebral spinal fluid and tumor tissue correlates with the malignancy grade of glioma patientsOncology Letters, 2014
- Predicting the likelihood of an isocitrate dehydrogenase 1 or 2 mutation in diagnoses of infiltrative gliomaNeuro-Oncology, 2014
- Genetics of adult gliomaCancer Genetics, 2012
- Frequent abnormalities of the immune system in gliomas and correlation with the WHO grading system of malignancyJournal of Neuroimmunology, 2010
- B7-H1 is correlated with malignancy-grade gliomas but is not expressed exclusively on tumor stem-like cellsNeuro-Oncology, 2009